{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-015108","form_type":"8-K","ticker":"ORMP","cik":"0001176309","company_name":"ORAMED PHARMACEUTICALS INC.","filed_at":"2024-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.568609+00:00","generated_at":"2026-06-05T22:46:01.521621+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Oramed plans new U.S. Phase 3 oral insulin trial after subpopulation analysis; JV with HTIT with $70M investment","bullets":["HTIT completed Phase 3 for oral insulin in China, in final regulatory approval; JV definitive agreement with $70M from HTIT, $20M from Oramed.","Oramed to initiate new Phase 3 U.S. oral insulin trial later 2024 under differentiated protocol after FDA discussions; earlier Phase 3 missed endpoints.","Scilex issued $101.875M secured note to Oramed at SOFR+8.5%; repayment began Dec 2023; warrants for 13M Scilex shares at $0.01.","Acquired PeriTech film-forming technology for topical/dermatology; entered exclusive licensing deal for royalty on net sales."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-015108","json":"https://secwatch.observer/filing/0001213900-24-015108.json","markdown":"https://secwatch.observer/filing/0001213900-24-015108.md","text":"https://secwatch.observer/filing/0001213900-24-015108.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1176309/000121390024015108/0001213900-24-015108-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1176309/000121390024015108/ea0200197-8k_oramed.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T22:46:01.521621+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}